Hopital Saint Joseph
- Address
- lock Available on a paid plan
Neoplasms (C04)
The department is conducting studies on a range of cancers, including head and neck cancer, colon carcinoma, and hepatocellular carcinoma, aiming to test new therapeutic combinations and improve survival outcomes.
- Evaluation of immunotherapy plus targeted agents
- Adjuvant treatment after surgical resection
- Radiation‑based strategies for locally advanced disease
Hopital Saint Joseph hosts 17 active trials with 40 investigators, focusing on innovative cancer care for patients in Marseille and beyond.
Cardiovascular Diseases (C14)
Research at the site addresses heart health by investigating therapies for atherosclerotic cardiovascular disease and elevated lipoprotein(a), with the goal of lowering cardiovascular events.
- Lipoprotein(a)‑targeted antisense therapy
- Prevention of myocardial infarction and coronary death
- Assessment of long‑term safety of novel agents
The hospital’s cardiovascular program integrates clinical research into routine care, offering patients access to cutting‑edge treatments.
Metabolic and Liver Diseases (C18)
Trials focus on liver‑related metabolic disorders such as Non‑alcoholic steatohepatitis and Metabolic Dysfunction‑Associated Steatohepatitis, as well as advanced hepatocellular carcinoma, to evaluate disease‑modifying therapies and improve liver function.
- Fibrosis regression with novel agents
- Combination of autophagy inhibitors and immunotherapy
- First‑line systemic options for unresectable liver cancer
With a multidisciplinary team, the site enrolls patients in studies that target both metabolic pathways and tumor control.
Skin and Connective Tissue Diseases (C17)
The clinic evaluates new treatments for chronic skin conditions including Atopic Dermatitis and Hidradenitis Suppurativa, seeking faster symptom relief and better quality of life.
- Biologic agents targeting inflammatory pathways
- Patient‑reported outcome measures of disease severity
- Long‑term safety and efficacy in moderate‑to‑severe cases
These dermatology studies provide regional patients with access to therapies not yet widely available.
Bacterial Infections and Mycoses (C01)
A focused investigation on Mycobacterium xenopi pulmonary infection aims to improve eradication rates using innovative inhaled antibiotic formulations.
- Comparison of liposomal inhaled therapy versus standard regimen
- Measurement of sputum conversion at three months
- Safety monitoring of respiratory adverse events
The infectious disease team collaborates closely with pulmonology to bring these trials to patients with difficult‑to‑treat lung infections.
Digestive System Diseases (C06)
Clinical work includes studies on gastrointestinal cancers such as small bowel adenocarcinoma and resectable colon carcinoma, evaluating pre‑operative chemotherapy and surgical outcomes.
- Neoadjuvant chemotherapy protocols for elderly patients
- Impact of treatment sequencing on recurrence‑free survival
- Biomarker‑driven personalization of therapy
By integrating trial data with routine gastroenterology practice, Hopital Saint Joseph advances care for complex digestive tract malignancies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 19 therapeutic areas and 15 of 145 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 138 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 30 by active trials.
lock +29 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +17 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hopital Saint Joseph
lock Showing 1 of 84 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A double-blind randomized, Phase III study of radiotherapy combined with cetuXimab + Xevinapant compared to radiotherapy combined with cetuximab (Standard of care) + placebo in patients with Locally advanced (LA) squamous cell carcinoma of the head and neck (SCCHN), unfit for high-dose cisplatin (XXL study) | Groupe Oncologie Radiotherapie Tete Cou | Phase III | Not Recruiting | Dec 2023 | Sep 2024 |
IMP list
lock Showing 1 of 145 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Bevacizumab | 8 | Unknown | 2019-11-21 | 2026-05-07 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.